Letters to the Editor
The positive impact of the new National Institute for Health and Care Excellence lipid guidelines on cardiovascular disease risk management in patients with psoriasis
First published: 15 June 2015
No abstract is available for this article.
References
- 1 National Institute for Health and Care Excellence. Lipid modification: cardiovascular risk assessment and the modification of blood lipids for the primary and secondary prevention of cardiovascular disease [CG181]. Available at: http://www.nice.org.uk/guidance/cg181 (last accessed 20 August 2015).
- 2 Editorial. Statins for millions more? Lancet 2014; 383: 669.
- 3Kristensen SL, McInnes IB, Sattar N. Psoriasis, psoriatic arthritis and cardiovascular risk. Ann Rheum Dis 2015; 74: 321–2.
- 4 National Institute for Health and Care Excellence. Psoriasis: The assessment and management of psoriasis [CG153]. Available at: http://www.nice.org.uk/guidance/cg153 (last accessed 20 August 2015).
- 5Sniderman AD, Williams K, Contois JH et al. A meta-analysis of low density lipoprotein cholesterol, non-high-density lipoprotein cholesterol, and apolipoprotein B as markers of cardiovascular risk. Circ Cardiovasc Qual Outcomes 2011; 4: 337–45.
- 6Neimann AL, Shin DB, Wang X et al. Prevalence of cardiovascular risk factors in patients with psoriasis. J Am Acad Dermatol 2006; 55: 829–35.
- 7Papp K, Poulin Y, Vieira A. Examining the risk of cardiovascular disease in patients with psoriasis: a critical review. J Cutan Med Surg 2013; 17: 89–105.
- 8 Scottish Intercollegiate Guidelines Network. Diagnosis and management of psoriasis and psoriatic arthritis in adults [SIGN 121]. Available at: http://sign.ac.uk/guidelines/fulltext/121/index.html (last accessed 20 August 2015).
- 9Brauchli YB, Jick SS, Meier CR. Statin use and risk of first-time psoriasis diagnosis. J Am Acad Dermatol 2011; 65: 77–83.
- 10Rajpara AN, Goldner R, Gaspari A. Psoriasis: can statins play a dual role? Dermatol Online J 2010; 16: 2.
